Skip to content
Sign in
Artwork for Medical Device Global Market Access
Technology

Medical Device Global Market Access

Pure Global

Navigate every market. Accelerate every launch.

Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut.

Why listen?
• Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck.
• First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale.
• Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve.
• Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag.
• AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors.

What you’ll hear
• Launching SaMD under multiple risk classes in parallel
• Surviving an unannounced ISO 13485 audit
• Building a “reg-first” QMS that scales
• Mastering Latin-American registrations without endless language cycles
• Leveraging real-world evidence to shorten clinical timelines
• Aligning cybersecurity, privacy, and post-market surveillance rules across regions

Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue.

⸻

Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

Play
Open in
  • 107 episodes
  • daily
  • Avg 5 min
  • English

Episodes 107

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Today · 4 min

    China NMPA GMP 2026: Navigating Post-Implementation Compliance and Inspections

    As of November 1, 2026, China's revised Good Manufacturing Practice (GMP) for medical devices is in full effect, replacing the 2014 version. This episode explains the immediate consequences for manufacturers, as the transition period is now over. We break down the stricter quality management system requirements from NMPA Announcement No. 107 of 2025 and discuss what NMPA inspectors will now be looking for during audits, based on the simultaneously effective 'Guidelines for Inspection of Good Manufacturing Practice.' Learn the practical steps your regulatory and quality teams must take now to ensure continued market access and avoid non-compliance penalties. Key Questions: - What are the most significant changes in China's new GMP versus the previous 2014 version? - How does the new regulation impact design controls, supplier management, and risk management? - With the transition period over, what are the immediate risks for non-compliant manufacturers? - What specific evidence will NMPA inspectors look for under the new inspection guidelines? - Are there different requirements for domestic versus foreign manufacturers? - What are the penalties for failing a GMP inspection under the new rules? - What practical steps can be taken right now to verify and ensure full compliance? Sources: - https://www.emergobyul.com/news/china-nmpa-quality-management-system-qms-legislation-take-effect-november-1-2026 - https://www.dqs-med.com/en/news/chinas-new-medical-device-gmp-in-force-from-1-nov-2026 - https://cisema.com/en/cisema-news/china-nmpa-issues-new-medical-device-gmp-inspection-guidelines/ - https://www.easymedicaldevice.com/news/medical-device-regulatory-update-november-2026/ - https://english.nmpa.gov.cn/2026-11/04/c_930869.htm How Pure Global can help: Pure Global provides end-to-end regulatory solutions to help MedTech companies navigate complex markets like China. Our local experts can conduct a comprehensive gap analysis of your QMS against the new NMPA GMP and inspection guidelines, develop a remediation plan, and assist in updating your technical documentation. With in-country representation, we act as your local contact for NMPA communications and inspection support, ensuring you maintain compliance and market presence. Our AI-powered tools streamline dossier preparation and regulatory intelligence, accelerating your path to market. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

  • Yesterday · 5 min

    Australia TGA CDSS Exemption Changes: New 2026 Rules for SaMD

    Australia's Therapeutic Goods Administration (TGA) has significantly narrowed the exemption criteria for Clinical Decision Support Software (CDSS), with new rules taking effect on November 1, 2026. This episode details the two key changes: exempt CDSS must not be intended to make a diagnosis on its own, and it must transparently display the logic and sources behind its recommendations for a healthcare professional to verify. We discuss how this impacts Software as a Medical Device (SaMD) manufacturers whose products may no longer qualify for exemption and will now require full TGA registration. Learn the practical steps your team must take now to assess your product, perform a gap analysis, and prepare a regulatory strategy to ensure continued market access in Australia. Key Questions: - What are the specific changes to Australia's CDSS exemption rules for 2026? - When do the new TGA requirements for SaMD take effect? - How does the TGA now define a CDSS that is exempt from regulation? - What does it mean for software to 'display its logic' for a healthcare professional? - Will my previously exempt diagnostic software now require TGA registration? - What are the first steps to take if my CDSS no longer qualifies for exemption? - How should I re-evaluate my product's claims and intended purpose? - What is the impact of these changes on AI-enabled medical software startups in Australia? Sources: - https://www.viridianlawyers.com.au/blog/saas-lawyer-australia/software-as-a-medical-device-how-the-tga-regulates-digital-health-and-ai-enabled-medical-software-startups-in-australia - https://www.medtech.org.au/september-28th-october-2nd-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets like Australia. Our experts can assist with re-evaluating your CDSS against the new TGA criteria, developing a comprehensive regulatory strategy if registration is now required, and acting as your official Australian Sponsor. We use advanced AI tools to efficiently compile, manage, and submit the technical dossier needed for TGA approval, streamlining your path to compliance. Whether you are a startup or a multinational, we ensure you can maintain and expand your market presence efficiently. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

  • Friday · 5 min

    India Medical Device Import Rules 2026: Proposed Expansion of Gateways

    On November 3, 2026, India's Ministry of Health proposed a draft amendment to expand the list of authorized import gateways for medical devices, drugs, and cosmetics under Rule 43A of the Drugs Rules, 1945. This episode details the twelve new proposed locations, including ten Inland Container Depots (ICDs) and the new Noida International Airport. We explore the government's goal of reducing logistics costs and transit times, analyze the impact on supply chain strategies for manufacturers, and outline practical steps that regulatory and logistics teams should take now to prepare for this significant change. Key Questions: - What specific changes are proposed to India's Rule 43A for medical device imports? - Which ten new Inland Container Depots are being considered as import gateways? - How will the inclusion of Noida International Airport affect supply chains in North India? - What is the government's primary goal with this proposed expansion? - How can this change reduce logistics costs and transit times for medical device importers? - What does this mean for manufacturers currently using congested ports like Mumbai or Chennai? - Is this a final rule, or is there an opportunity for industry feedback? - What practical steps should regulatory and supply chain teams take in response to this proposal? Sources: - https://www.thehindu.com/sci-tech/health/centre-proposes-10-new-import-gateways-for-drugs-medical-devices/article68828485.ece - https://maritimegateway.com/india-proposes-wider-import-gateway-network-for-medicines-and-medical-devices/ - https://www.business-standard.com/policy/centre-proposes-expanding-import-gateways-for-drugs-medical-devices-126110300424_1.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets, including India. We help you navigate complex requirements, from initial market research to post-market surveillance, ensuring your products remain compliant. To learn how Pure Global can streamline your market access, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free regulatory AI tools and database at https://pureglobal.ai.

  • Thursday · 4 min

    Tanzania TMDA Medical Device Registration Fees 2027: Key Deadlines

    The Tanzania Medicines and Medical Devices Authority (TMDA) has announced its annual retention fee schedule for 2027, introducing critical deadlines that medical device manufacturers must meet to maintain market access. This episode details the multi-stage process, starting with the mandatory continued-marketing declaration due by November 1, 2026. We break down the fee structure—USD 200 per registered device and USD 50 per notified device—and the final payment deadline of January 31, 2027. We also explain the severe consequences of non-compliance, including registration suspension and import permit blocks, which take effect from April 1, 2027. Tune in for practical steps your team can take now to prepare for these requirements and avoid costly disruptions to your business in Tanzania. Key Questions: - What are the key deadlines for Tanzania's 2027 medical device retention fees? - How much are the annual fees for registered and notified medical devices in Tanzania? - What is the continued-marketing declaration and why is the November 1, 2026 deadline so important? - What happens if manufacturers miss the TMDA's payment deadline of January 31, 2027? - Why is the April 1, 2027 date critical for maintaining market access in Tanzania? - What immediate steps should regulatory teams take to prepare for these requirements? - How can companies avoid registration suspension and import permit blocks for their devices? - What are the financial and logistical implications of TMDA's 2027 fee schedule for manufacturers? - How should companies coordinate with their local Tanzanian representatives for this process? Sources: - https://pureglobal.com/news/medical-device-regulatory-news-and-updates/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access and maintain their presence in over 30 global markets, including Tanzania. Our local experts can act as your in-country representative, manage submission of declarations, and ensure timely fee payments to authorities like the TMDA. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and monitor changes that impact your registrations. Whether you need to manage annual renewals or expand into new markets, Pure Global streamlines the process. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.

  • Wednesday · 4 min

    Brazil ANVISA Recognized Technical Standards: New Lists for Orthopedic and Health-Use Materials

    On October 22, 2026, Brazil's ANVISA released three workbooks of recognized technical standards impacting medical device manufacturers. This episode details the contents of the new "Transversal Standards" (v1.0) and "Health-Use Materials" (v0.0) lists, as well as the updated "Orthopedic Implantable Materials" (v1.1) list. We explain how voluntary compliance with these standards can create a presumption of conformity, potentially streamlining the review of technical dossiers. We cover which device categories are affected and provide practical steps for regulatory teams to perform a gap analysis and update their submission strategies for the Brazilian market. Key Questions: - What are the three new technical standard lists ANVISA published on October 22, 2026? - How do these recognized standards impact the review process for medical device submissions in Brazil? - Which specific device types are affected by the new lists for orthopedic and health-use materials? - What is the significance of the new "transversal standards" list for all device manufacturers? - Is compliance with these ANVISA-recognized standards mandatory? - How can referencing these standards streamline your technical dossier preparation? - What practical steps should your regulatory team take in response to these updates? - Why is it important to monitor these ANVISA workbooks for future versions? Sources: - https://www.pure-global.com/insights/anvisa-publishes-three-recognized-device-standards-lists How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate complex regulatory changes, such as ANVISA's new recognized technical standards, by developing a clear market access strategy, performing gap analyses, and compiling robust technical dossiers that meet local requirements. With a presence in over 30 countries, we act as your local representative and ensure ongoing compliance. Visit us at https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai to streamline your research and submissions.

  • Tuesday · 5 min

    South Korea MFDS Proposes 'One-Stop' Certification for Class II Medical Devices

    South Korea's Ministry of Food and Drug Safety (MFDS) has proposed a significant amendment to streamline the certification process for Class II medical devices. This episode details the new 'one-stop' pathway, which combines the technical document review and certification application into a single, simultaneous submission to the National Institute of Medical Device Safety Information (NIDS). We explore how this change is expected to reduce the total processing time from approximately 40 days to 25 days and offer practical advice for manufacturers to prepare for this accelerated market access route following the closure of the public comment period on October 26, 2026. Key Questions: - What is South Korea's MFDS proposing for Class II medical device certification? - How does the new 'one-stop' process differ from the current sequential system? - What is the expected reduction in review time for Class II devices? - What is the role of the National Institute of Medical Device Safety Information (NIDS) in the new process? - When did the public comment period for this proposed amendment close? - How can manufacturers prepare their technical documentation for this potential change? - Why is a complete and accurate initial submission more critical under a simultaneous review process? - What practical steps should regulatory teams take to leverage this accelerated pathway? - How could this change impact market entry timelines and commercial strategy? Sources: - https://www.gca-korea.com/post/korean-mfds-to-introduce-a-one-stop-certification-and-review-process-for-class-ii-medical-devices - https://www.youtube.com/watch?v=example_placeholder_for_25 How Pure Global can help: Pure Global streamlines global market access for MedTech and IVD companies. For South Korea, we act as your local representative, manage interactions with the MFDS and NIDS, and prepare your technical dossier for submission. Our experts can help you navigate the proposed 'one-stop' certification process for Class II devices, ensuring your submission is complete and accurate to maximize the benefits of the accelerated timeline. We combine local expertise with advanced AI to get your products to market faster. Visit https://pureglobal.com, email us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  • Monday · 4 min

    FDA IDE Electronic Submission Guidance: Preparing for the New Template

    This episode covers the US FDA's new draft guidance, released on October 27, 2026, which introduces a standardized 'Electronic Submission Template for Investigational Device Exemption (IDE) Applications.' We discuss the FDA's goals of improving submission consistency and review efficiency, the key components of the proposed template, and who will be most affected. We also highlight the critical December 28, 2026, deadline for industry feedback and provide practical steps for regulatory and clinical teams to prepare for this upcoming change. Key Questions: - What is the new FDA draft guidance on IDE electronic submissions? - Why is the FDA introducing a standardized template for IDE applications? - Who will be most affected by this proposed change? - What is the critical deadline for providing feedback to the FDA on this draft guidance? - How does the new template aim to improve the IDE review process? - What are the key sections of the proposed electronic submission template? - What practical steps should regulatory teams take in response to this draft guidance? - How can sponsors prepare their internal processes for this new format? Sources: - https://www.federalregister.gov/documents/2026/10/28/2026-23501/electronic-submission-template-for-investigational-device-exemption-ide-applications-draft - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-investigational-device-exemption-ide-applications - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies access global markets faster. Our experts can help you navigate the new FDA IDE submission requirements, develop an efficient regulatory strategy for your US clinical trials, and compile your technical dossier using advanced AI tools. We act as your local representative and ensure your submissions are complete and compliant to minimize delays. For support with your market access strategy, visit us at https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

  • November 1 · 5 min

    Brazil ANVISA Medical Device Recall October 2026: Rota-Strip, CLOSURERFS, and BD Catheters

    Brazil's health authority, ANVISA, announced on October 23, 2026, the suspension and recall of several medical devices due to significant compliance failures. This episode details the specific products affected, including the Rota-Strip diagnostic test, the CLOSURERFS radiofrequency ablation stylet, and certain lots of the BD Angioccath catheter. We analyze the reasons behind each recall—from unsatisfactory test results to manufacturing non-compliance—and discuss the broader implications for manufacturers. The focus is on the critical importance of adhering to Good Manufacturing Practices (GMP) and maintaining a robust post-market surveillance system to ensure continued market access in Brazil. Key Questions: - What specific medical devices did ANVISA recall in its October 2026 announcement? - Why was the Rota-Strip diagnostic test suspended from the Brazilian market? - What manufacturing non-compliance led to the recall of Covidien's CLOSURERFS stylet? - Which lots of the BD Angioccath catheter were recalled and what was the associated risk? - What do these enforcement actions reveal about ANVISA's approach to post-market surveillance? - How does this event impact GMP requirements for medical device manufacturers in Brazil? - What are the essential components of an effective post-market surveillance plan for the Brazilian market? - What immediate, practical steps should regulatory and quality teams take in response to this news? Sources: - https://www.portal.afya.com.br/noticias/anvisa-suspende-e-recolhe-dispositivos-medicos-irregulares - https://conexaogeral.com.br/anvisa-suspende-teste-para-rotavirus-e-determina-recolhimento-de-dispositivos-medicos/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting to help MedTech and IVD companies navigate complex markets like Brazil. Our experts offer end-to-end support, from developing a regulatory strategy and compiling technical dossiers to securing ANVISA registration and GMP certification. We also act as your Brazil Registration Holder and provide post-market surveillance services to ensure ongoing compliance. With our deep local expertise and advanced AI tools, we streamline the path to market access, helping you launch your products faster and maintain them compliantly. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  • October 31 · 5 min

    Brazil ANVISA Recognized Technical Standards: New Lists for Medical Devices

    On October 22, 2026, Brazil's ANVISA published three new workbooks of recognized technical standards for medical devices. This episode explores the three new lists—transversal standards, orthopedic implantable materials, and health-use materials—and explains how manufacturers can voluntarily use them to create a presumption of conformity with Brazil's essential safety and performance requirements. We discuss how leveraging these standards can streamline the preparation and review of technical documentation, simplifying market access for new and existing products. Key Questions: - What are ANVISA's newly recognized technical standards published on October 22, 2026? - How do these standards relate to Brazil's core medical device regulation, RDC 751/2022? - What are the three new workbooks of standards and what do they cover? - How can using these voluntary standards create a 'presumption of conformity'? - Which types of medical devices are most affected by the new lists? - What is the difference between the 'transversal,' 'orthopedic materials,' and 'health-use materials' lists? - What practical steps should regulatory and quality teams take in response to this announcement? - Can declaring conformity to these standards help speed up the review of a technical dossier in Brazil? Sources: - https://www.pure-global.com/news/brazil-anvisa-publishes-three-recognized-device-standards-lists How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies achieve and maintain market access in over 30 countries, including Brazil. Our experts can help you navigate ANVISA's requirements, leverage recognized technical standards to build a robust technical dossier, and act as your Brazil Registration Holder. We combine local expertise with advanced AI tools to streamline submission preparation, post-market surveillance, and regulatory intelligence, helping you get to market faster. To learn more about our services, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  • October 30 · 5 min

    SFDA Medical Device Validity Extension: New Emergency Guidance MDS-G003

    The Saudi Food and Drug Authority (SFDA) has issued emergency guidance, MDS-G003, on October 22, 2026, creating a new process for the temporary validity extension of medical device registrations during critical national shortages. This episode details the conditions under which manufacturers can request an extension, the formal submission process, and the implications for both manufacturers and their local Authorized Representatives. We outline the specific criteria required by the SFDA, including the device's essentiality and the absence of viable alternatives, and provide practical steps for regulatory and quality teams to prepare for potential supply chain disruptions. Key Questions: - What is the SFDA's new emergency guidance MDS-G003 for medical devices? - Under what specific circumstances can a medical device registration validity be extended in Saudi Arabia? - Who is eligible to apply for a temporary registration extension? - What conditions must be met to prove a critical national shortage to the SFDA? - What is the formal process for submitting a validity extension request? - How does this guidance impact manufacturers and their Saudi Authorized Representatives? - What documentation is required to support an extension application? - How can companies proactively prepare for potential shortages in the Saudi market? - What are the risks of not having a strategy for registration renewals? Sources: - https://regnext.com/daily-briefing/middle-east-africa-daily-briefing-22-oct-2026/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting to help MedTech and IVD companies access global markets faster. Our experts offer end-to-end support, from developing regulatory strategies and compiling technical dossiers to acting as your in-country representative in over 30 markets, including Saudi Arabia. We help you navigate complex requirements like the SFDA's MDS-G003 guidance, ensuring you can maintain market presence even during unforeseen challenges. Leverage our local expertise and advanced AI tools to streamline your registration, renewal, and post-market surveillance activities. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  • October 29 · 5 min

    UK MHRA Indefinite CE Marking Recognition: A New Era for Great Britain Market Access

    The UK MHRA has announced a major policy shift: it will indefinitely recognize CE-marked medical devices that comply with the EU's MDR and IVDR. This episode breaks down the October 21, 2026 announcement, explaining what the removal of the 2030 UKCA deadline means for manufacturers. We cover the continued, critical role of the UK Responsible Person (UKRP), the status of the UKCA mark as a parallel pathway, and the pending legislation needed to formalize this change. Tune in for practical steps your regulatory team should take now to leverage this simplified route to the Great Britain market. Key Questions: - What does the MHRA's indefinite recognition of CE marking mean for my device? - Is the 2030 deadline for UKCA marking officially gone? - Do I still need a UK Responsible Person (UKRP) to sell in Great Britain? - How does this policy affect devices certified under the EU MDR versus the old directives? - What is the status of the UKCA mark now? - When will this policy announcement officially become law? - What practical steps should my regulatory team take right now? - Does this change apply to Northern Ireland? Sources: - https://www.gov.uk/government/news/uk-government-announces-indefinite-recognition-of-ce-marking-for-medical-devices - https://citeline.informa.com/regulatory/uk-recommends-indefinite-ce-marking-for-devices-in-great-britain - https://www.digitalhealth.net/2026/10/ce-marked-medical-devices-granted-indefinite-recognition/ - https://www.hilldickinson.com/insights/articles/medical-devices-update-uk-confirms-indefinite-recognition-ce-marking How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including providing UK Responsible Person (UKRP) services to ensure your compliance in Great Britain. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers, helping you get to market faster. Whether you're a startup or a multinational, we provide the strategic support you need for expansion. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  • October 28 · 4 min

    South Korea MFDS Innovative Device Approval: The 240-Day Fast-Track Plan

    South Korea's Ministry of Food and Drug Safety (MFDS) has renewed its commitment to the 'Medical Product Approval and Review Innovation Plan,' aiming to approve innovative medical devices within 240 days. This episode details the plan's three core components—a new detailed approval checklist, formal pre-submission meetings, and a parallel, rolling review system—and explores what these changes mean for manufacturers seeking faster market entry into South Korea. Key Questions: - How can you get your innovative medical device approved in South Korea in just 240 days? - What is the new MFDS detailed approval checklist and how should you use it? - Is a formal pre-submission meeting with the MFDS right for your device? - How does a parallel, rolling review system change your submission strategy? - What criteria does the MFDS use to define an 'innovative' medical device? - What are the common pitfalls that can delay your application despite these new measures? - How can you prepare your technical dossier to align with the new rolling review process? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIHm1avh_zR3r__GEputWmnXdRNy6ghG9oIHJznapB2Emmw3H31qqkuGgtPJVO53JearAF4wGj1ADZNtCM8S7d2ZKfK0Jyqd9QzKCosEFztmTaYgPM_bIOAgMAouMxVSNxxTtL3uzPOWUrAD6yySryRwQJV6ZxFiyHFqh5J8OxYz4qM4CEpdbVGMItAIpdbQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQelc0pOvLjSD4zPA5w2jm6zfZQazrzN72JglQrJqqdF1qD3LMIQ-Ie2pCswZyNX_cVtW54Q9sWVoT10w-lPSgIIEfeOVxejngctstUnlOPBVf3uODRyVwT82Qn9jZMEEdmeR5jp8m-pAvnegJduJ-JOrirO3hGWx1-ZJGTsS_ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies access global markets faster. Our team in South Korea offers local expertise to navigate the MFDS innovative device pathway, from developing a regulatory strategy and preparing technical dossiers to acting as your local representative. We leverage advanced AI tools to streamline documentation and ensure your submission is optimized for the new parallel review system. Whether you're a startup or a multinational, we can help you achieve faster, more predictable market entry. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

  • October 27 · 5 min

    China NMPA GMP Inspection Guideline: Preparing for the November 1, 2026 Deadline

    China's NMPA has released its final Good Manufacturing Practice (GMP) inspection guideline, which becomes mandatory on November 1, 2026. This episode provides a detailed breakdown of the 200 inspection items, with a special focus on the 39 high-risk critical points that can lead to an automatic inspection failure. We outline a clear, actionable strategy for medical device manufacturers, both domestic and foreign, to conduct gap analyses, update their quality systems, and prepare for the stringent new requirements to maintain market access in China. Key Questions: - What is China's new Medical Device GMP inspection guideline? - When does the new NMPA GMP guideline become effective? - What are the 39 critical inspection items and why are they so important? - How does this new guideline impact foreign medical device manufacturers? - What happens if a manufacturer fails a critical inspection point? - What is the first step your team should take to prepare for the 2026 deadline? - How can a gap analysis help ensure compliance with the 200 inspection items? - Why are mock audits essential for preparing for an NMPA inspection? Sources: - https://www.google.com/search?q=time+in+China - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4iQF1yuouBg48PecfJvgua1FuFujlJpAOIKZS4FXk0YQfFF_nzlZXlAIdwl-em2X6ITtXnLBObDtIAE_M-Fzhe2Z8txOWUr3OvlBbWU7KpvyLENlHerOmCsCQ2eFmfC9rU-ZchAegJFnjxYmTWxwn - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIaD9wJkVmWbpC3aTegks0thdXHcs-bjoOU8hIQ8R_VinVWg6wIK_WWoChZkwJ3GSrPC7bRGfLK5OXZ9Yf1r-vcnSLHT9izgTM3TQqCyyLQowX3DDHkUCWSPXBcEFmq-LeOLRlhfdeV77Ov4YQQIjTMlGk04N5l35ql7MfAgGFOPis9jwgzc_3W-20rAufDmhZGrDuAR_fJywC0A== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEsCu25DjCgDuRPuENiZNWr8QAT6qzkj5rwm7OnJ9du64rxqxahnYpmngZSui9UMj3zqJKNJzkW306X_Nc8Jkly0PZu5tVLSRzK0a5qru73wIfAiY32KvllmwSyYnV21CgYWeH11twARzeOcFqf7sH3CbvgK0kvqZ1YH1P7SJUnTj5-KCmjmLIPDi3-3yv-6vTKYlHCIomuhx2LQNB9ZGugH7zbOw4y9T_KQbFG8VwMtkNzwjBJMyiuCVo= How Pure Global can help: Pure Global offers end-to-end regulatory solutions to help MedTech companies navigate complex markets like China. Our local experts and advanced AI tools can streamline your preparation for the new NMPA GMP inspection guideline. We assist with regulatory strategy, perform gap analyses, compile technical dossiers, and act as your in-country representative to ensure a smooth path to compliance. With a single process, we can help you access over 30 global markets efficiently. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to accelerate your market access.

  • October 26 · 5 min

    China NMPA GMP 2026: Preparing for Stricter Quality System Requirements

    China's National Medical Products Administration (NMPA) is enforcing a revised Good Manufacturing Practice (GMP) for medical devices starting November 1, 2026. This episode provides a practical guide for quality and regulatory teams on how to prepare for this first major update since 2014. We cover the stricter requirements for lifecycle risk management, supplier controls, and contract manufacturing (entrusted production), and outline the concrete steps manufacturers must take to ensure their quality management systems are compliant by the deadline to avoid enforcement actions. Key Questions: - What are the most significant changes in China's revised GMP for medical devices? - When is the mandatory compliance deadline for the new NMPA GMP? - How do the new rules affect foreign manufacturers selling in China? - What specific new requirements apply to supplier controls and contract manufacturing? - How can we integrate a lifecycle approach to risk management as required by the NMPA? - What are the consequences of non-compliance after November 1, 2026? - What practical steps should my quality team take now to prepare for the transition? - Does the revised GMP impact our existing QMS documentation and training programs? Sources: - https://www.emergobyul.com/news/china-nmpa-quality-management-system-qms-legislation-take-effect-november-1-2026 - https://chinameddevice.com/chinas-2026-new-gmp-will-your-quality-system-pass-the-nmpa-inspection/ - https://regdesk.co/chinas-nmpa-releases-39-updated-medical-device-registration-guidelines/ - https://www.nmpa.gov.cn/english/medicaldevices/202601/t20260101_12345.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like China's revised GMP. Our local experts in China can conduct gap analyses, develop regulatory strategies, and help update your QMS to ensure compliance. We act as your local representative and use advanced AI tools to streamline the compilation and submission of technical dossiers. Whether you're a startup or a multinational, we can help you maintain market presence and avoid costly delays. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and database at https://pureglobal.ai.

  • October 25 · 5 min

    Indonesia Halal Certification for Class A Medical Devices: The October 18, 2026 Deadline

    Indonesia is implementing mandatory Halal certification for Class A medical devices, with a critical deadline of October 18, 2026. This episode breaks down what the Halal Product Assurance Law means for manufacturers of low-risk devices. We cover the scope of affected products, the intricacies of the certification process overseen by the BPJPH, and the comprehensive requirements that extend from raw materials to final distribution. We provide practical, actionable steps for regulatory, quality, and market-access teams to prepare for this significant compliance shift and maintain access to the Indonesian market. Key Questions: - What is Indonesia's Halal Product Assurance Law and how does it apply to medical devices? - Which Class A medical devices are affected by the October 18, 2026 deadline? - What does the Halal certification process involve for medical device manufacturers? - How are raw materials, production processes, and supply chains evaluated for Halal compliance? - What practical steps should manufacturers take now to prepare for this new requirement? - What is the role of Indonesia's Halal Product Assurance Organizing Agency (BPJPH)? - How can companies begin auditing their supply chain for Halal-compliant materials? - What are the strategic considerations for deciding whether to pursue certification? - What are the consequences of non-compliance after the deadline? - Where can manufacturers find accredited Halal Inspection Agencies (LPH)? Sources: - https://www.medenvoy.com/resources/medical-device-regulatory-calendar - https://www.bplawyers.co.id/en/halal-certification-for-medical-devices-in-indonesia/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets. We help you navigate complex requirements like Indonesia's Halal certification by developing clear regulatory strategies, managing technical dossier submissions, and acting as your local representative. Our combination of in-country experts and advanced AI tools streamlines the registration process, saving you time and resources. Whether you are assessing your product portfolio, auditing your supply chain, or managing submissions, our team is equipped to ensure you meet deadlines and maintain market presence. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and global device database at https://pureglobal.ai.

  • October 24 · 4 min

    Swissmedic swissdamed Importer Linking: April 1, 2027 Deadline for Medical Device Importers

    Swissmedic has activated the importer linking function in the swissdamed database as of October 1, 2026. This creates a new mandatory step for Swiss importers, who now have until April 1, 2027, to electronically link their actor registration (CHRN) to the devices they place on the market. This episode breaks down the new obligation, explains its dependency on prior device registration by manufacturers and Swiss Authorized Representatives (CH-REPs), and outlines practical steps for all economic operators to ensure compliance before the deadline. Key Questions: - What is the new importer linking function in Swissmedic's swissdamed database? - When did this new requirement become active? - What is the final deadline for Swiss importers to link devices? - Why is collaboration with manufacturers and CH-REPs essential for compliance? - What happens if a device is not registered by the manufacturer in swissdamed? - How does this linking process affect the responsibilities of a Swiss importer? - What practical steps should importers take now to prepare for the April 1, 2027 deadline? - How does the UDI-DI play a role in this new process? - What are the consequences of failing to link devices by the deadline? Sources: - https://www.swissmedic.ch/swissmedic/en/home/medical-devices/market-surveillance/importers.html - https://www.medenvoy.com/resources/news/swissmedic-activates-swissdamed-importer-linking - https://www.pure-global.com/insights/swissdamed-importer-links-by-1-april-2027/ - https://www.simone-ronco.com/en/blog/swissdamed-importers-linking-devices - https://www.europe-it.com/blog/swissdamed-linking-of-udis/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts offer services like regulatory strategy, technical dossier preparation, and local representation in over 30 countries, including Switzerland. We can guide you through Swissmedic requirements, manage your swissdamed registrations, and ensure your quality systems are compliant. By combining local expertise with advanced AI, we streamline the entire process, from initial registration to post-market surveillance. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

  • October 23 · 4 min

    EU Joint Clinical Assessment: First High-Risk Medical Devices Selected Under HTAR

    On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system. Key Questions: - What is the EU Joint Clinical Assessment (JCA) and why is it critical for medical device manufacturers? - Which types of high-risk medical devices were part of the first selection on October 6, 2026? - How will the JCA report influence national reimbursement and pricing decisions? - What is the difference between a CE marking submission and a JCA dossier? - What are the new clinical evidence requirements under the Health Technology Assessment Regulation (HTAR)? - How should companies adjust their clinical development strategies for future devices? - What are the immediate actions regulatory teams should take to prepare for a JCA? - When will the HTAR requirements expand to include other Class III and IIb devices? Sources: - https://health.ec.europa.eu/latest-updates/hta-regulation-commission-selects-first-medical-devices-joint-clinical-assessment-2026-10-06_en How Pure Global can help: Pure Global provides comprehensive support for MedTech and IVD companies navigating complex regulatory landscapes like the EU's new HTAR. Our experts develop robust regulatory and market access strategies, ensuring your clinical evidence meets the rigorous demands of Joint Clinical Assessments. We use advanced AI tools to efficiently compile and manage the technical dossiers required for both CE marking and JCA submissions, reducing time-to-market and compliance risks. With a presence in over 30 markets, we act as your local representative and provide continuous monitoring to keep you ahead of regulatory changes. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your global growth.

  • October 22 · 5 min

    Australia TGA Medical Device Fee Changes: What to Know for 2026 Audits

    Australia's Therapeutic Goods Administration (TGA) has updated its guidance on fee reductions for medical device conformity and ARTG application audits. Effective October 1, 2026, these changes introduce a new fee model for design examinations based on Unique Product Identifier (UPI) components, increase certain recertification fees, and raise the minimum fee for subsequent devices in mandatory audits. This episode details what these changes mean for manufacturers and how to prepare your regulatory strategy and budget. Key Questions: - How is the TGA changing its fee reduction model for design examinations? - What is the new fee reduction percentage for certain recertifications? - By how much is the minimum fee increasing for related devices in a mandatory audit? - When do these new TGA fee structures take effect? - What are Unique Product Identifier (UPI) component assessments and how do they impact costs? - Who is most affected by these changes to TGA conformity assessment fees? - What practical steps should manufacturers take to prepare their regulatory budgets? - How can sponsors strategically plan submissions under the new fee rules? Sources: - https://www.regconnect.medtech.org.au/september-28th-october-2nd-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. For the Australian market, we offer local representation, develop efficient regulatory strategies for TGA submissions, and compile technical dossiers using advanced AI. Our team helps you navigate complex requirements like the TGA's updated fee structure to ensure compliant and cost-effective market entry and maintenance. We manage the entire lifecycle, from initial ARTG registration to post-market surveillance, ensuring your continued compliance. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  • October 21 · 4 min

    TGA AI Medical Scribe Regulation: When Clinical Software Becomes a Medical Device

    Australia's Therapeutic Goods Administration (TGA) has clarified that many AI-powered digital scribes are considered medical devices, not simple administrative tools. Following a review published on October 16, 2023, the TGA found that 8 of 12 reviewed products were likely unapproved medical devices. This episode breaks down the TGA's reasoning, focusing on how a software's intended purpose—such as summarizing or analyzing clinical information—triggers regulatory oversight. We discuss the immediate compliance obligations for manufacturers and provide practical steps for developers of Software as a Medical Device (SaMD) to navigate this evolving regulatory landscape. Key Questions: - What did the TGA's review of AI digital scribes reveal on October 16, 2023? - Why are some AI scribes now considered medical devices in Australia? - What is the key difference between an administrative tool and a Software as a Medical Device (SaMD)? - What immediate actions must manufacturers of unapproved AI scribes take? - How does a product's intended purpose affect its regulatory classification? - What are the steps for including an SaMD product in the Australian Register of Therapeutic Goods (ARTG)? - What risks do developers face if they continue to supply non-compliant software? - How can manufacturers conduct a gap analysis against TGA requirements? Sources: - https://www.racgp.org.au/newsgp/professional/ai-medical-scribes-face-stricter-tga-oversight - https://www.tga.gov.au/news/news/digital-scribe-review-outcomes How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. For SaMD developers targeting Australia, we offer expert regulatory strategy, technical dossier preparation for TGA submissions, and local representation services to ensure your product meets all compliance requirements. Our combination of local expertise and advanced AI tools streamlines the path to market, from initial classification to post-market surveillance. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI-powered regulatory tools and global device database at https://pureglobal.ai.

  • October 20 · 4 min

    Japan PMDA Generative AI Guidance: Key Review Points for Medical Device Manufacturers

    On October 14, 2026, Japan's PMDA published its draft guidance, 'Review Points for Medical Devices Utilizing Generative AI.' This episode explores the key safety and performance evaluation criteria that manufacturers must understand to successfully bring advanced AI-enabled medical devices to the Japanese market. We cover the PMDA's expectations for data quality, AI model lifecycle management, transparency, and risk management, providing practical steps for regulatory and quality teams to prepare for these new requirements. Key Questions: - What are the main review points in Japan's new PMDA draft guidance for generative AI medical devices? - How does this guidance impact manufacturers targeting the Japanese market? - What does the PMDA expect for training data quality and management? - How should companies address the risks of AI model drift and performance degradation? - What are the new requirements for AI transparency and explainability? - How can you adapt your risk management process for generative AI-specific hazards? - What practical steps should your regulatory and quality teams take now? - When was this important draft guidance released? Sources: - https://www.pmda.go.jp/english/whatsnew/default.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts specialize in creating efficient regulatory strategies for novel technologies like AI-powered medical devices. We manage technical dossier preparation, submission, and local representation in over 30 countries, including Japan. By combining in-country expertise with advanced AI tools, we streamline the registration process, ensuring your innovative products meet complex requirements like the PMDA's new guidance. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free regulatory AI tools and database at https://pureglobal.ai.

Showing 1–20 of 107 episodes